Cargando…

Renal sympathetic denervation alleviates myocardial fibrosis following isoproterenol-induced heart failure

The aim of the present study was to determine if renal sympathetic denervation (RSD) may alleviate isoproterenol-induced left ventricle remodeling, and to identify the underlying mechanism. A total of 70 rats were randomly divided into control (n=15), sham operation (n=15), heart failure (HF) with s...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Neng, Zheng, Xiaoxin, Qian, Jin, Yao, Wei, Bai, Lu, Hou, Guo, Qiu, Xuan, Li, Xiaoyan, Jiang, Xuejun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5647034/
https://www.ncbi.nlm.nih.gov/pubmed/28849013
http://dx.doi.org/10.3892/mmr.2017.7255
_version_ 1783272192058851328
author Wang, Neng
Zheng, Xiaoxin
Qian, Jin
Yao, Wei
Bai, Lu
Hou, Guo
Qiu, Xuan
Li, Xiaoyan
Jiang, Xuejun
author_facet Wang, Neng
Zheng, Xiaoxin
Qian, Jin
Yao, Wei
Bai, Lu
Hou, Guo
Qiu, Xuan
Li, Xiaoyan
Jiang, Xuejun
author_sort Wang, Neng
collection PubMed
description The aim of the present study was to determine if renal sympathetic denervation (RSD) may alleviate isoproterenol-induced left ventricle remodeling, and to identify the underlying mechanism. A total of 70 rats were randomly divided into control (n=15), sham operation (n=15), heart failure (HF) with sham operation (HF + sham; n=20) and HF with treatment (HF + RSD; n=20) groups. The HF model was established by subcutaneous injection of isoproterenol; six weeks later, 1eft ventricular internal diameter at end-systole (LVIDs), left ventricular systolic posterior wall thickness (LVPWs), 1eft ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS) were measured. Plasma norepinephrine (NE), angiotensin II (Ang II) and aldosterone (ALD) levels were measured by ELISA. Myocardial collagen volume fraction (CVF) was determined by Masson's staining. Reverse transcription-quantitative polymerase chain reaction was used to determine the mRNA expression levels of ventricular transforming growth factor-β (TGF-β), connective tissue growth factor (CTGF) and microRNAs (miRs), including miR-29b, miR-30c and miR-133a. The results demonstrated that LVIDs and LVPWs in the HF + RSD group were significantly decreased compared with the HF + sham group. By contrast, LVFS and LVEF in the HF + RSD group were significantly increased compared with the HF + sham group. RSD significantly reduced the levels of plasma NE, Ang II and ALD. CVF in the HF + RSD group was reduced by 38.1% compared with the HF + sham group. Expression levels of TGF-β and CTGF were decreased, whereas those of miR-29b, miR-30c and miR-133a were increased, in the HF + RSD group compared with the HF + sham group. These results indicated that RSD alleviates isoproterenol-induced left ventricle remodeling potentially via downregulation of TGF-β/CTGF and upregulation of miR-29b, miR-30c and miR-133a. RSD may therefore be an effective non-drug therapy for the treatment of heart failure.
format Online
Article
Text
id pubmed-5647034
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-56470342017-10-24 Renal sympathetic denervation alleviates myocardial fibrosis following isoproterenol-induced heart failure Wang, Neng Zheng, Xiaoxin Qian, Jin Yao, Wei Bai, Lu Hou, Guo Qiu, Xuan Li, Xiaoyan Jiang, Xuejun Mol Med Rep Articles The aim of the present study was to determine if renal sympathetic denervation (RSD) may alleviate isoproterenol-induced left ventricle remodeling, and to identify the underlying mechanism. A total of 70 rats were randomly divided into control (n=15), sham operation (n=15), heart failure (HF) with sham operation (HF + sham; n=20) and HF with treatment (HF + RSD; n=20) groups. The HF model was established by subcutaneous injection of isoproterenol; six weeks later, 1eft ventricular internal diameter at end-systole (LVIDs), left ventricular systolic posterior wall thickness (LVPWs), 1eft ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS) were measured. Plasma norepinephrine (NE), angiotensin II (Ang II) and aldosterone (ALD) levels were measured by ELISA. Myocardial collagen volume fraction (CVF) was determined by Masson's staining. Reverse transcription-quantitative polymerase chain reaction was used to determine the mRNA expression levels of ventricular transforming growth factor-β (TGF-β), connective tissue growth factor (CTGF) and microRNAs (miRs), including miR-29b, miR-30c and miR-133a. The results demonstrated that LVIDs and LVPWs in the HF + RSD group were significantly decreased compared with the HF + sham group. By contrast, LVFS and LVEF in the HF + RSD group were significantly increased compared with the HF + sham group. RSD significantly reduced the levels of plasma NE, Ang II and ALD. CVF in the HF + RSD group was reduced by 38.1% compared with the HF + sham group. Expression levels of TGF-β and CTGF were decreased, whereas those of miR-29b, miR-30c and miR-133a were increased, in the HF + RSD group compared with the HF + sham group. These results indicated that RSD alleviates isoproterenol-induced left ventricle remodeling potentially via downregulation of TGF-β/CTGF and upregulation of miR-29b, miR-30c and miR-133a. RSD may therefore be an effective non-drug therapy for the treatment of heart failure. D.A. Spandidos 2017-10 2017-08-16 /pmc/articles/PMC5647034/ /pubmed/28849013 http://dx.doi.org/10.3892/mmr.2017.7255 Text en Copyright: © Wang et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Wang, Neng
Zheng, Xiaoxin
Qian, Jin
Yao, Wei
Bai, Lu
Hou, Guo
Qiu, Xuan
Li, Xiaoyan
Jiang, Xuejun
Renal sympathetic denervation alleviates myocardial fibrosis following isoproterenol-induced heart failure
title Renal sympathetic denervation alleviates myocardial fibrosis following isoproterenol-induced heart failure
title_full Renal sympathetic denervation alleviates myocardial fibrosis following isoproterenol-induced heart failure
title_fullStr Renal sympathetic denervation alleviates myocardial fibrosis following isoproterenol-induced heart failure
title_full_unstemmed Renal sympathetic denervation alleviates myocardial fibrosis following isoproterenol-induced heart failure
title_short Renal sympathetic denervation alleviates myocardial fibrosis following isoproterenol-induced heart failure
title_sort renal sympathetic denervation alleviates myocardial fibrosis following isoproterenol-induced heart failure
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5647034/
https://www.ncbi.nlm.nih.gov/pubmed/28849013
http://dx.doi.org/10.3892/mmr.2017.7255
work_keys_str_mv AT wangneng renalsympatheticdenervationalleviatesmyocardialfibrosisfollowingisoproterenolinducedheartfailure
AT zhengxiaoxin renalsympatheticdenervationalleviatesmyocardialfibrosisfollowingisoproterenolinducedheartfailure
AT qianjin renalsympatheticdenervationalleviatesmyocardialfibrosisfollowingisoproterenolinducedheartfailure
AT yaowei renalsympatheticdenervationalleviatesmyocardialfibrosisfollowingisoproterenolinducedheartfailure
AT bailu renalsympatheticdenervationalleviatesmyocardialfibrosisfollowingisoproterenolinducedheartfailure
AT houguo renalsympatheticdenervationalleviatesmyocardialfibrosisfollowingisoproterenolinducedheartfailure
AT qiuxuan renalsympatheticdenervationalleviatesmyocardialfibrosisfollowingisoproterenolinducedheartfailure
AT lixiaoyan renalsympatheticdenervationalleviatesmyocardialfibrosisfollowingisoproterenolinducedheartfailure
AT jiangxuejun renalsympatheticdenervationalleviatesmyocardialfibrosisfollowingisoproterenolinducedheartfailure